| Literature DB >> 23599024 |
R C Tschumper1, A Dispenzieri, R S Abraham, K J Henderson, D F Jelinek.
Abstract
Monoclonal gammopathies (MGs) are hematological diseases characterized by high levels of a monoclonal immunoglobulin (Ig) or M-protein. Within this group are patients with more than one M-protein, referred to as double MGs (DMGs). The M-proteins in DMG patients may have different heavy chain (HC) isotypes that are associated with different light chains (LCs), or different HCs that are LC matched. In this study, we examined the clonal relatedness of the M-proteins in the latter type in a cohort of 14 DMG patients. By using PCR, we identified 7/14 DMG patients that expressed two Ig HC isotypes with identical Ig HC variable (IGHV), diversity (IGHD), joining (IGHJ), and complementarity determining region (HCDR3) sequences. Two additional DMG patients had two Ig transcripts using the same IGHV, IGHD and IGHJ genes but with slight differences in variable region or HCDR3 mutations. LC analysis confirmed that a single LC was expressed in 3/7 DMG patients with identical HC transcripts and in the two DMGs with highly similar transcripts. The PCR findings were confirmed by immunofluorescence for HC and LC expression. Clonally related HC-dissimilar/LC-matched DMGs may occur often and defines a new subtype of MG that may serve as a tool for studies of disease pathogenesis.Entities:
Year: 2013 PMID: 23599024 PMCID: PMC3641320 DOI: 10.1038/bcj.2013.12
Source DB: PubMed Journal: Blood Cancer J ISSN: 2044-5385 Impact factor: 11.037
Characteristics of DMG patient cohort
| 1 | Relapsed MM | IgGκ/IgAκ | 50 | 1.8 | 1.4 | 3.3 | — |
| 2 | Relapsed MM | IgGλ/IgAλ | 34 | 2.7 | 2.0 | 0.5 | — |
| 3 | MM Untxt | IgGκ/IgAκ | 74 | 7.7 | 2.8 | 0.3 | — |
| 4 | AL Txt | IgGλ/IgAλ | 38 | 0.2 | NQ | 0.8 | — |
| 5 | AL Untxt | IgGλ/IgAλ | 5 | 0 | NQ | 0.3 | — |
| 6 | MM Untxt | IgGκ/IgAκ | 54 | 2.4 | 3.2 | SV | — |
| 7 | Relapsed MM | IgGλ/IgAλ | 11 | 1.4 | NQ | NQ | — |
| 8 | MGUS | IgGλ/IgMλ | 2 | ND | — | 2.7 | SV |
| 9 | WM/MGUS Txt | IgGκ/IgMκ | 12 | 0.4 | — | 3.0 | 3.1 |
| 10 | AL Untxt | IgGλ/IgAλ | 10 | 0.4 | 0.4 | 1.0 | — |
| 11 | Relapsed MM | IgGλ/IgAλ | 13 | 4.2 | 0.5 | SV | — |
| 12 | WM | IgGκ/IgMκ | 7 | 2.8 | — | 0.2 | 2.1 |
| 13 | MGUS | IgGλ/IgMλ | 5 | 0 | — | 0.2 | 1.6 |
| 14 | MGUS | IgGκ/IgMκ | 2 | 0 | — | 0.9 | SV |
Abbreviations: AL, primary light chain amyloidosis; Ig, immunoglobulin; MGUS, monoclonal gammopathy of undetermined significance; MM, multiple myeloma; ND, not determined; NQ, the M-spike was present but too small to be quantified; PC, plasma cells; PCLI, plasma cell labeling index; SV, the M-spikes were recorded as a single value; Txt, treated; Untxt, untreated; WM, Waldenstrom's macroglobulinemia.
M-protein immunoglobulin on immunofixation (g/dl).
IGHV, IGHD, and IGHJ gene usage for DMG isotypes
| 1 | IgG | 1–46 | 1–26 | J4*02 | 13.9 | TFLGGGGDF |
| IgA | 1–46 | 1–26 | J4*02 | 13.9 | TFLGGGGDF | |
| 2 | IgG | 2–5 | 6–19 | J5*02 | 8.3 | AGTRLGMAVSGKEKSAWFDP |
| IgA | 2–5 | 6–19 | J5*02 | 8.3 | AGTRLGMAVSGKEKSAWFDP | |
| 3 | IgG | 4–39 | 5–5 | J6*02 | 10 | ASQSAYSSSLPLSV |
| IgA | 4–39 | 5–5 | J6*02 | 10 | ASQSAYSSSLPLSV | |
| 4 | IgG | 3–48 | 6–19 | J6*03 | 7.1 | ARDNGWSKSYYYFHMDV |
| IgA | 3–48 | 6–19 | J6*03 | 7.1 | ARDNGWSKSYYYFHMDV | |
| 5 | IgG | 3–73 | 2–21 | J6*03 | 11 | TVPMDYRAFDGYYYMDV |
| IgA | No clonal sequence determined | |||||
| 6 | IgG | 3–48 | 2–15 | J4*02 | 6.7 | AREAP |
| IgA | 3–48 | 2–15 | J4*02 | 7.9 | AREAP | |
| 7 | IgG | 4–39 | 6–6 | J5*02 | 13.6 | ARDGLTARALEVKNLFDP |
| IgA | 4–39 | 6–6 | J5*02 | 13.6 | ARDGLTARALEVKNLFDP | |
| 8 | IgG | 5–51 | 3–22 | J5*02 | 0.8 | ARRGRYDSSGYQT |
| IgM | 5–51 | 3–22 | J5*02 | 0.8 | ARRGRYDSSGYQT | |
| 9 | IgG | 3–30 | 2–8 | J5*02 | 11.7 | ATGGFDS |
| IgM | 3–7 | 5–12 | J4*02 | 10.8 | VRLGSGYPDI | |
| 10 | IgG | 1–2 | 2–15 | J2*01 | 4.7 | ARDAGWGGLYWHFDL |
| IgA | 1–2 | 2–15 | J2*01 | 4.7 | ARDAGWGGLYWHFDL | |
| 11 | IgG | 3–23 | 2–8 | J4*02 | 8.6 | ASSLGVYSITGPFDI |
| IgA | 3–23 | 2–8 | J4*02 | 10.0 | ASSLGVYSITGPFDI | |
| 12 | IgG | 4–31 | 3–22 | J6*01 | 15.6 | ARVVRPEAAVLVTFPLRRGGMDV |
| IgM | 4–61 | 4–23 | J4*02 | 0.4 | AREATVVPYFNY | |
| 13 | IgG | 4–39 | 3–22 | J4*02 | 5.8 | ARHRSGYYDTSGYYQFDS |
| IgM | 3–7 | 6–19 | J4*02 | 2.5 | ASNMAVPGD | |
| IgM | 4–61 | 6–13 | J4*02 | 6.6 | ARVGRQLVDS | |
| 14 | IgG | 3-30-3 | 4–17 | J4*02 | 6.3 | ARDAGYDTLTGYYLALDYW |
| IgM | 3–7 | 2–8 | J5*02 | 12.1 | ARGNGGVL | |
| IgM | 4-30-4 | 5–18 | J5*02 | 3.3 | AREPWGYGSGNI | |
| IgM | 5–51 | 6–19 | J4*02 | 5.2 | ARSAFEGWRDGWYSVDY | |
Abbreviations: Ig, immunoglobulin; IGHV, Ig HC variable; IGHD, Ig HC diversity; IGHJ, Ig HC joining.
Changes in HCDR3 amino acid sequence in Patient 6 are in bold. Patient numbers are identical to numbers shown in Table 1.
% Mut=percent mutation from GL sequence in the IGHV region.
True bi- or polyclonal.
Figure 1DMG sequence alignments. (a) Sequence alignment of patient 2 representing those patient samples that had identical sequences in the variable and HCDR3s in two different HC transcripts. (b) Sequence alignment of patient 11 showing shared and distinct somatic mutations in the Ig HC V region, but identical HCDR3s in IgG and IgA transcripts. (c) Sequence alignment of patient 6 showing shared and distinct somatic mutations, and highly homologous but not identical HCDR3s in IgG and IgA transcripts. Blue denotes replacement mutations resulting in AA change; green denotes silent mutations resulting in AA preservation; HFR, heavy chain framework regions; HCDR, heavy chain complementarity determining regions.
LC gene usage for κ (IGKV) and λ (IGLV) isotypes in DMG patients
| 1 | κ | IGKV3-11 | M | ND | NA |
| 2 | λ | ND | NA | IGLV1-47 | M |
| 3 | κ | IGKV1-27 | UM | IGLV4-69 | M |
| 4 | λ | Multiple | M/UM | Multiple | M/UM |
| 5 | λ | IGKV1-39 | M | Multiple | M/UM |
| 6 | κ | IGKV1-33 | UM | ND | NA |
| 7 | λ | IGKV2-28 | UM | Multiple | M |
| 8 | λ | IGKV4-1 | UM | IGLV6-57 | UM |
| 9 | κ | Multiple | M | ND | NA |
| 10 | λ | ND | NA | IGLV2-23 | M |
| 11 | λ | ND | NA | IGLV3-25 | M |
| 12 | κ | IGKV1-5 | M | IGLV6-57 | M |
| 13 | λ | Multiple | M/UM | Multiple | M |
| 14 | κ | IGKV1-16 | M | ND | NA |
Abbreviations: IGKV, Ig Kappa variable; IGLV, Ig lambda variable; LC, light chain; M, mutated (⩾2% deviation from germline (GL) sequence); ND, no readable sequence detected; NA, not applicable; UM, unmutated (<2% deviation from GL sequence); .
HC transcripts were identical for these patients.
HC transcripts were not identical, but clonally related for these patients.
Figure 2HC staining of DMG patient. BM MNCs from patient 2 were collected onto glass slides and stained with anti-IgM FITC (green), anti-IgA TRITC (red) and anti-IgG labeled with CF350 (blue). The image is over saturated for the FITC channel to show that no IgM FITC-labeled PCs were found. ( × 60 magnification).
Figure 3LC staining of DMG patients. (a) BM MNCs from patient 2 were collected onto glass slides and stained with anti-κ AMCA (blue), anti-λ FITC (green) and counterstained with PI (red). A single-λ LC was found by PCR in patient 2. (b) BM MNCs from patient 4 were stained as in a. Both κ and λ LCs were found by PCR in patient 4. ( × 60 magnification).